December 12, 2022
  • Amgen Inc. has agreed to buy biotechnology company Horizon Therapeutics PLC in a deal worth $27.8 billion, the largest health care acquisition of the year. The all-cash deal is equal to a nearly 20 percent premium over Horizon’s closing stock price on Friday. The deal will also give Amgen another chance to build its portfolio of rare-disease treatments after it closed in October a roughly $3.7 billion acquisition of ChemoCentryx, which focuses on autoimmune disease drugs. (Articles here, here, here, and here)